Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary

Pedro Augusto Sampaio Rocha-Filho

doi:10.1055/s-0045-1809332

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(09): s00451809332
DOI: 10.1055/s-0045-1809332

Point of View

Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary

Pedro Augusto Sampaio Rocha-Filho

¹Universidade Federal de Pernambuco, Centro de Ciências Médicas, Área Acadêmica de Neuropsiquiatria, Recife PE, Brazil.

²Universidade de Pernambuco, Hospital Universitário Oswaldo Cruz, Serviço de Neurologia, Recife PE, Brazil.

› Author Affiliations

Abstract

Medication-overuse headache affects 1 to 2% of the global population and is often associated with chronic migraine. This condition significantly impacts the lives of patients, as well as their families, and it poses a major economic burden due to lost productivity and medical costs. The present narrative review is part of a controversy session. We argue that reversing the behavior of overusing symptomatic pain medications is important for the treatment of this type of headache. To support this argument, the article reviews and critically analyzes the relevant literature on the subject.

Keywords

Headache - Headache Disorders, Secondary - Migraine Disorders - Tension-Type Headache - Therapeutics - Analgesics - Review

Bibliographical Record
Pedro Augusto Sampaio Rocha-Filho. Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary. Arq Neuropsiquiatr 2025; 83: s00451809332.
DOI: 10.1055/s-0045-1809332

Full Text

References

References
1 Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C. et al. Medication overuse headache. Nat Rev Dis Primers 2023; 9 (01) 5
2 Headache Classification Committee of the International Headache Society. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 (01) 1-211
3 Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB. et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019; 18 (09) 891-902
4 Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine Progression: A Systematic Review. Headache 2019; 59 (03) 306-338
5 Kowacs F, Roesler CAP, Piovesan ÉJ, Sarmento EM, de Campos HC, Maciel Jr JA. et al. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arq Neuropsiquiatr 2019; 77 (07) 509-520
6 Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia 2016; 36 (04) 371-386
7 Alves ALM, Silva IK, Lemos PHP, Torres VL, Arraes EC, Rocha-Filho PAS. FRAMES protocol versus simple advice for medication-overuse headache: a prospective, randomized, controlled clinical trial. Acta Neurol Belg 2021; 121 (05) 1259-1264
8 Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 2011; 18 (03) 396-401
9 Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M. et al; COMOESTAS Consortium. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014; 34 (06) 426-433
10 Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z. et al; the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 2014; 34 (09) 645-655
11 Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2018; 38 (02) 225-236
12 Schwedt TJ, Hentz JG, Sahai-Srivastava S, Murinova N, Spare NM, Treppendahl C. et al; MOTS Investigators. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 2022; 98 (14) e1409-e1421
13 Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, Jensen RH. et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol 2020; 77 (09) 1069-1078
14 Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML. et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. Headache 2021; 61 (01) 125-136
15 Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J. et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 2021; 41 (03) 340-352
16 Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 2020; 21 (01) 114
17 Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U. et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 2019; 92 (20) e2309-e2320
18 Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-823
19 Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331 (1-2) 48-56
20 Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P. et al; SAMOHA Study Group. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol 2014; 24 (08) 1289-1297
21 Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N. et al; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47 (02) 170-180
22 Kowacs PA, Sampaio Rocha-Filho PA, Peres MFP, Edvinsson L. The history and rationale of the development of new drugs for migraine treatment. Arq Neuropsiquiatr 2023; 81 (12) 1084-1097
23 Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S. et al. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia 2024; 44 (09) 3331024241269735